Pamapimod
Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment[1].
Product Specifications
CAS Number
449811-01-2
Product Name Alternative
Ro4402257; R1503
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; p38 MAPK
Type
Reference compound
Related Pathways
Autophagy; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Pamapimod.html
Purity
99.92
Solubility
DMSO : ≥ 34 mg/mL
Smiles
O=C1C(OC2=CC=C(F)C=C2F)=CC3=CN=C(NC(CCO)CCO)N=C3N1C
Molecular Formula
C19H20F2N4O4
Molecular Weight
406.38
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
P38α; p38β
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
EDAR (ectodysplasin A Receptor, DL, ED1R, ED3, ED5, EDA-A1R, EDA1R, EDA3, FLJ94390)
